GlassScriptPhysician profile
Bruce R Kava
NPI 1265461826
$44,174.28
in general payments reported to CMS, 2019-2025
26 companies · $11K in 2025
The $11K reported for 2025 was more than what 94% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $545 · 2021: $1,105 · 2022: $1,522 · 2023: $894 · 2024: $3,987 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,615 · Food and Beverage: $6,199 · Travel and Lodging: $2,681 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,615.00 |
| Food and Beverage | $6,198.74 |
| Travel and Lodging | $2,681.12 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $15,257.08 | 2019 | |
| Endo USA, INC. | $7,730.48 | 2024-2025 | Xiaflex |
| Coloplast Corp | $5,017.17 | 2019-2025 | Titan, Speedicath |
| Endo Pharmaceuticals INC. | $4,719.61 | 2019-2024 | Xiaflex, Aveed |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,578.01 | 2019 | |
| Boston Scientific Corporation | $2,063.67 | 2019-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, General - Erectile Dysfunction |
| Procept Biorobotics Corporation | $1,963.26 | 2020-2025 | Aquabeam Robotic System |
| Abbvie INC. | $398.15 | 2019-2025 | |
| Janssen Biotech, INC. | $331.23 | 2019-2025 | Erleada |
| Teleflex LLC | $318.87 | 2023-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $221.68 | 2019-2024 | Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $207.43 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $204.35 | 2022 | |
| Axonics, INC. | $186.20 | 2022-2023 | Axonics |
| Neotract INC. | $132.13 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $118.01 | 2019-2024 | |
| Antares Pharma, INC. | $116.05 | 2019-2023 | Tlando, Xyosted |
| Osprey Medical INC | $115.62 | 2021 | |
| Ambu INC. | $115.36 | 2020-2025 | |
| Verity Pharmaceuticals INC. | $94.64 | 2024-2025 | Tlando |
| Integra Lifesciences Corporation | $92.11 | 2021 | |
| Merck Sharp & Dohme LLC | $74.72 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.65 | 2021 | |
| Ferring Pharmaceuticals INC. | $33.42 | 2025 | Adstiladrin |
| Urogen Pharma, INC. | $17.84 | 2023 | Jelmyto |
| Allergan, INC. | $17.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Kava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.